Now showing items 1-20 of 31

    • A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. 

      Eccleston, A; Bentley, A; Dyer, M; Strydom, A; Vereecken, W; George, A; Rahman, N (2017-04)
      Objectives To evaluate the long-term cost-effectiveness of germline BRCA1 and BRCA2 (collectively termed "BRCA") testing in women with epithelial ovarian cancer, and testing for the relevant mutation in first- and second-degree ...
    • Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis. 

      Phi, X-A; Houssami, N; Hooning, MJ; Riedl, CC; Leach, MO; Sardanelli, F; Warner, E; Trop, I; Saadatmand, S; Tilanus-Linthorst, MMA; Helbich, TH; van den Heuvel, ER; de Koning, HJ; Obdeijn, I-M; de Bock, GH (2017-11)
      Introduction Women with a strong family history of breast cancer (BC) and without a known gene mutation have an increased risk of developing BC. We aimed to investigate the accuracy of screening using annual mammography ...
    • Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. 

      Barton, S; Zabaglo, L; A'Hern, R; Turner, N; Ferguson, T; O'Neill, S; Hills, M; Smith, I; Dowsett, M (2012-05)
      Background The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility ...
    • Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. 

      Saya, S; Killick, E; Thomas, S; Taylor, N; Bancroft, EK; Rothwell, J; Benafif, S; Dias, A; Mikropoulos, C; Pope, J; Chamberlain, A; Gunapala, R; SIGNIFY Study Steering Committee; Izatt, L; Side, L; Walker, L; Tomkins, S; Cook, J; Barwell, J; Wiles, V; Limb, L; Eccles, D; Leach, MO; Shanley, S; Gilbert, FJ; Hanson, H; Gallagher, D; Rajashanker, B; Whitehouse, RW; Koh, D-M; Sohaib, SA; Evans, DG; Eeles, RA (2017-07)
      In the United Kingdom, current screening guidelines for TP53 germline mutation carriers solely recommends annual breast MRI, despite the wide spectrum of malignancies typically seen in this group. This study sought to ...
    • Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. 

      Ballinger, ML; Best, A; Mai, PL; Khincha, PP; Loud, JT; Peters, JA; Achatz, MI; Chojniak, R; Balieiro da Costa, A; Santiago, KM; Garber, J; O'Neill, AF; Eeles, RA; Evans, DG; Bleiker, E; Sonke, GS; Ruijs, M; Loo, C; Schiffman, J; Naumer, A; Kohlmann, W; Strong, LC; Bojadzieva, J; Malkin, D; Rednam, SP; Stoffel, EM; Koeppe, E; Weitzel, JN; Slavin, TP; Nehoray, B; Robson, M; Walsh, M; Manelli, L; Villani, A; Thomas, DM; Savage, SA (2017-12)
      Importance Guidelines for clinical management in Li-Fraumeni syndrome, a multiple-organ cancer predisposition condition, are limited. Whole-body magnetic resonance imaging (WBMRI) may play a role in surveillance of this ...
    • Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. 

      Merker, JD; Oxnard, GR; Compton, C; Diehn, M; Hurley, P; Lazar, AJ; Lindeman, N; Lockwood, CM; Rai, AJ; Schilsky, RL; Tsimberidou, AM; Vasalos, P; Billman, BL; Oliver, TK; Bruinooge, SS; Hayes, DF; Turner, NC (2018-10)
      PURPOSE.—:Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology and the College of American Pathologists ...
    • Circulating tumor DNA-From bench to bedside. 

      Lim, JSJ; Janku, F; Yap, TA (2017-05)
      In the era of personalized medicine, tumor sampling is paramount to enable the assessment of actionable molecular aberrations to help rationalize and guide treatment decisions. Longitudinal tracking of such aberrations may ...
    • Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme. 

      Davidson, M; Aronson, LI; Howard-Reeves, J; Bryant, H; Cutts, RJ; Hulkki-Wilson, S; Kouvelakis, K; Kalaitzaki, E; Watkins, D; Starling, N; Rao, S; Cardenosa, ML; Begum, R; Rana, I; Lazaro-Alcausi, R; Terlizzo, M; Wotherspoon, A; Brown, G; Swansbury, J; Lord, CJ; Cunningham, D; Chau, I; Chong, IY (2019-11)
      Introduction The MYC proto-oncogene is among the most commonly dysregulated genes in human cancers. We report screening data from the iMYC trial, an ongoing phase II study assessing ibrutinib monotherapy in advanced ...
    • Comparison of optimised endovaginal vs external array coil T2-weighted and diffusion-weighted imaging techniques for detecting suspected early stage (IA/IB1) uterine cervical cancer. 

      Downey, K; Attygalle, AD; Morgan, VA; Giles, SL; MacDonald, A; Davis, M; Ind, TEJ; Shepherd, JH; deSouza, NM (2016-04)
      Objective To compare sensitivity and specificity of endovaginal versus external-array coil T2-W and T2-W + DWI for detecting and staging small cervical tumours.Methods Optimised endovaginal and external array coil MRI at ...
    • Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. 

      Sumanasuriya, S; Omlin, A; Armstrong, A; Attard, G; Chi, KN; Bevan, CL; Shibakawa, A; IJzerman, MJ; De Laere, B; Lolkema, M; Lorente, D; Luo, J; Mehra, N; Olmos, D; Scher, H; Soule, H; Stoecklein, NH; Terstappen, LWMM; Waugh, D; de Bono, JS (2018-06)
      Context In advanced prostate cancer (PC), there is increasing investigation of circulating biomarkers, including quantitation and characterization of circulating tumour cells and cell-free nucleic acids, for therapeutic ...
    • Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. 

      Lawler, M; Alsina, D; Adams, RA; Anderson, AS; Brown, G; Fearnhead, NS; Fenwick, SW; Halloran, SP; Hochhauser, D; Hull, MA; Koelzer, VH; McNair, AGK; Monahan, KJ; Näthke, I; Norton, C; Novelli, MR; Steele, RJC; Thomas, AL; Wilde, LM; Wilson, RH; Tomlinson, I; Bowel Cancer UK Critical Research Gaps in Colorectal Cancer Initiative (2018-01)
      Objective Colorectal cancer (CRC) leads to significant morbidity/mortality worldwide. Defining critical research gaps (RG), their prioritisation and resolution, could improve patient outcomes.Design RG analysis was conducted ...
    • Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study. 

      Johns, LE; Coleman, DA; Swerdlow, AJ; Moss, SM (2017-01)
      Background Population breast screening has been implemented in the UK for over 25 years, but the size of benefit attributable to such programmes remains controversial. We have conducted the first individual-based cohort ...
    • Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer. 

      Kemp, Z; Turnbull, A; Yost, S; Seal, S; Mahamdallie, S; Poyastro-Pearson, E; Warren-Perry, M; Eccleston, A; Tan, M-M; Teo, SH; Turner, N; Strydom, A; George, A; Rahman, N (2019-05-03)
      Importance Increasing BRCA1 and BRCA2 (collectively termed herein as BRCA) gene testing is required to improve cancer management and prevent BRCA-related cancers.Objective To evaluate mainstream genetic testing using ...
    • Genetic predisposition to prostate cancer. 

      Benafif, S; Eeles, R (2016-12)
      Introduction Prostate cancer (PrCa) is the commonest non-cutaneous cancer in men in the UK. Epidemiological evidence as well as twin studies points towards a genetic component contributing to aetiology.Sources of data Key ...
    • "I was seen by a radiologist, but unfortunately I can't remember the name and I still have questions. What should I do?" Radiologists should give thoughts to improve service professionalism and patient esteem. 

      Gutzeit, A; Fischmann, A; Forstner, R; Goette, R; Herzog, B; Kurtz, C; Hebler, C; Ladinger, A; Froehlich, JM; Blautzik, J; Kolokythas, O; Matoori, S; Kos, S; Reischauer, C; Schefer, H; Dubsky, P; Gampenrieder, SP; Hergan, K; Gaissmaier, W; Koh, D-M; Meissnitzer, M (2020-02-13)
      BACKGROUND:The aim of the study is to investigate how well patients remember the radiologist's name after a radiological examination, and whether giving the patient a business card improves the patient's perception of the ...
    • Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. 

      Page, EC; Bancroft, EK; Brook, MN; Assel, M; Hassan Al Battat, M; Thomas, S; Taylor, N; Chamberlain, A; Pope, J; Raghallaigh, HN; Evans, DG; Rothwell, J; Maehle, L; Grindedal, EM; James, P; Mascarenhas, L; McKinley, J; Side, L; Thomas, T; van Asperen, C; Vasen, H; Kiemeney, LA; Ringelberg, J; Jensen, TD; Osther, PJS; Helfand, BT; Genova, E; Oldenburg, RA; Cybulski, C; Wokolorczyk, D; Ong, K-R; Huber, C; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oosterwijk, JC; van Zelst-Stams, W; Cook, J; Rosario, DJ; Domchek, S; Powers, J; Buys, S; O'Toole, K; Ausems, MGEM; Schmutzler, RK; Rhiem, K; Izatt, L; Tripathi, V; Teixeira, MR; Cardoso, M; Foulkes, WD; Aprikian, A; van Randeraad, H; Davidson, R; Longmuir, M; Ruijs, MWG; Helderman van den Enden, ATJM; Adank, M; Williams, R; Andrews, L; Murphy, DG; Halliday, D; Walker, L; Liljegren, A; Carlsson, S; Azzabi, A; Jobson, I; Morton, C; Shackleton, K; Snape, K; Hanson, H; Harris, M; Tischkowitz, M; Taylor, A; Kirk, J; Susman, R; Chen-Shtoyerman, R; Spigelman, A; Pachter, N; Ahmed, M; Ramon Y Cajal, T; Zgajnar, J; Brewer, C; Gadea, N; Brady, AF; van Os, T; Gallagher, D; Johannsson, O; Donaldson, A; Barwell, J; Nicolai, N; Friedman, E; Obeid, E; Greenhalgh, L; Murthy, V; Copakova, L; Saya, S; McGrath, J; Cooke, P; Rønlund, K; Richardson, K; Henderson, A; Teo, SH; Arun, B; Kast, K; Dias, A; Aaronson, NK; Ardern-Jones, A; Bangma, CH; Castro, E; Dearnaley, D; Eccles, DM; Tricker, K; Eyfjord, J; Falconer, A; Foster, C; Gronberg, H; Hamdy, FC; Stefansdottir, V; Khoo, V; Lindeman, GJ; Lubinski, J; Axcrona, K; Mikropoulos, C; Mitra, A; Moynihan, C; Rennert, G; Suri, M; Wilson, P; Dudderidge, T; IMPACT Study Collaborators; Offman, J; Kote-Jarai, Z; Vickers, A; Lilja, H; Eeles, RA (2019-12)
      Background Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 ...
    • Modeling the prevention of colorectal cancer from the combined impact of host and behavioral risk factors. 

      Frampton, M; Houlston, RS (2017-03)
      Purpose This study investigated the utility of modeling modifiable lifestyle risk factors in addition to genetic variation in colorectal cancer (CRC) screening/prevention.Methods We derived a polygenic risk score for CRC ...
    • National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting. 

      Brizmohun Appayya, M; Adshead, J; Ahmed, HU; Allen, C; Bainbridge, A; Barrett, T; Giganti, F; Graham, J; Haslam, P; Johnston, EW; Kastner, C; Kirkham, APS; Lipton, A; McNeill, A; Moniz, L; Moore, CM; Nabi, G; Padhani, AR; Parker, C; Patel, A; Pursey, J; Richenberg, J; Staffurth, J; van der Meulen, J; Walls, D; Punwani, S (2018-07)
      OBJECTIVES:To identify areas of agreement and disagreement in the implementation of multi-parametric magnetic resonance imaging (mpMRI) of the prostate in the diagnostic pathway. MATERIALS AND METHODS:Fifteen UK experts ...
    • Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. 

      Seibert, TM; Fan, CC; Wang, Y; Zuber, V; Karunamuni, R; Parsons, JK; Eeles, RA; Easton, DF; Kote-Jarai, Z; Al Olama, AA; Garcia, SB; Muir, K; Grönberg, H; Wiklund, F; Aly, M; Schleutker, J; Sipeky, C; Tammela, TL; Nordestgaard, BG; Nielsen, SF; Weischer, M; Bisbjerg, R; Røder, MA; Iversen, P; Key, TJ; Travis, RC; Neal, DE; Donovan, JL; Hamdy, FC; Pharoah, P; Pashayan, N; Khaw, K-T; Maier, C; Vogel, W; Luedeke, M; Herkommer, K; Kibel, AS; Cybulski, C; Wokolorczyk, D; Kluzniak, W; Cannon-Albright, L; Brenner, H; Cuk, K; Saum, K-U; Park, JY; Sellers, TA; Slavov, C; Kaneva, R; Mitev, V; Batra, J; Clements, JA; Spurdle, A; Teixeira, MR; Paulo, P; Maia, S; Pandha, H; Michael, A; Kierzek, A; Karow, DS; Mills, IG; Andreassen, OA; Dale, AM; PRACTICAL Consortium* (2018-01-10)
      Objectives To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age.Design Analysis of genotype, PCa status, and age to ...
    • Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study. 

      Callender, T; Emberton, M; Morris, S; Eeles, R; Eeles, R; Kote-Jarai, Z; Pharoah, PDP; Pashayan, N (2019-12-20)
      Background The United States Preventive Services Task Force supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55-69. Knowing how the potential benefits and harms of ...